Leadership is about driving change at scale and requires engaging both hearts and minds. Sally Susman, Executive Vice President and Chief Corporate Affairs Officer at Pfizer, provides insights ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors.

Two former Pfizer executives published a statement saying they support management as it gets pressured for changes by activist investor Starboard Value. The ex-Pfizer executives, Ian Read and ...

Pfizer is making these changes in preparation for integrating Seagen once the $43 billion merger closes, expected in late 2023 or early 2024. For now, the two companies are operating independently ...

Pfizer told U.S. District Judge Jennifer Rochon of Manhattan, in a brief opposing Do No Harm’s bid for a preliminary injunction, that the law permits the use of racial selection criteria when it ...

WALTHAM, MASSACHUSETTS / ACCESS Newswire / February 4, 2025 / Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI ...